- testing |
| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 7 Nov 2025 | 27 Oct 2025 |
| Torrent Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2025 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on 30-Sep-25. Results for quarter and half year ended 30-Sep-25 (As Per Bse Announcement dated on 07/11/2025) | ||
| Board Meeting | 28 Jul 2025 | 21 Jul 2025 |
| Torrent Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2025 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results with limited review on Consolidated basis of the Company for the quarter ended on 30-Jun-25. In the above meeting the Board would also consider the Issue of Unsecured or Secured Redeemable Non Convertible Debentures or Bonds by way of private placement. Outcome of Board Meeting dated 28-Jul-25 (As per BSE Announcement Dated on 28/07/2025) | ||
| Board Meeting | 29 Jun 2025 | 29 Jun 2025 |
| Disclosure pursuant to Regulation 30 read with Schedule III and Regulation 51 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing Regulations) | ||
| Board Meeting | 20 May 2025 | 13 May 2025 |
| Torrent Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2025 inter alia to consider and approve the Audited Financial Results of the Company for the year ended on 31-Mar-25; Recommendation of final dividend; Taking enabling resolutions for raising of funds by issue of Equity Shares including Convertible Bonds / Debentures through QIP and / or Depository Receipts or any other modes. Outcome of Board meeting dated 20-May-25 (As Per BSE Announcement Dated on :20.05.2025) | ||
| Board Meeting | 24 Jan 2025 | 13 Jan 2025 |
| TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2025 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on 31-Dec-24. The Board would also consider payment of Interim Dividend for the year 2024-25. Outcome of Board Meeting Dated 24-Jan-25. Dividend Updates (As per BSE Announcement Dated on 24/01/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.